Laura Sepp-Lorenzino oversees all platform and pipeline research activities across in vivo and ex vivo (engineered cell therapy) areas as Intellia’s Chief Scientific Officer. Before joining Intellia, she was vice president, Head of Nucleic Acid Therapies, Research, and member of the External Innovation team at Vertex Pharmaceuticals, Inc. She also served as vice president, entrepreneur-in-residence at Alnylam Pharmaceuticals, Inc., a leader in the development of RNAi Therapeutics. At Alnylam, she was responsible for the Hepatic Infectious Disease Strategic Therapeutic Area, championed extra hepatic siRNA delivery, and was active in licensing and partnering.
Laura spent 14 years at Merck & Co., most recently having served as executive director and department head, RNA Therapeutics Discovery Biology. In this role, she was responsible for identification and optimization of siRNAs and delivery vehicles, advancement of preclinical candidates, and development of an siRNA-conjugate platform to expand the repertoire of tissues accessible to in vivo siRNA delivery. Laura also has expertise in oncology drug discovery and development acquired earlier in her career by leading the Cancer Research Department at Merck West Point and working as an assistant lab member and assistant attending molecular biologist at Memorial Sloan-Kettering Cancer Center.
She received her professional degree in Biochemistry from the University of Buenos Aires, Argentina and both her M.S. and Ph.D. in Biochemistry from New York University. Laura holds professional affiliations with key scientific organizations, including the Oligonucleotide Therapeutics Society, the American Society for Gene and Cell Therapy, the European Society of Gene and Cell Therapy, and the New York Academy of Sciences, as well as a number of oncology societies. She also sits on the scientific advisory board of Thermo Fisher Scientific, Lodo Therapeutics, the U.K. Nucleic Acid Therapy Accelerator and is a member of Taysha Gene Therapies’ board of directors.
What is Laura Sepp-Lorenzino's net worth?
The estimated net worth of Laura Sepp-Lorenzino is at least $707,663.97 as of January 8th, 2024. Dr. Sepp-Lorenzino owns 43,927 shares of Intellia Therapeutics stock worth more than $707,664 as of November 14th. This net worth estimate does not reflect any other assets that Dr. Sepp-Lorenzino may own. Additionally, Dr. Sepp-Lorenzino receives an annual salary of $670,580.00 as EVP at Intellia Therapeutics. Learn More about Laura Sepp-Lorenzino's net worth.
How old is Laura Sepp-Lorenzino?
Dr. Sepp-Lorenzino is currently 63 years old. There are 8 older executives and no younger executives at Intellia Therapeutics. The oldest executive at Intellia Therapeutics is Dr. David Lebwohl M.D., Executive VP & Chief Medical Officer, who is 69 years old. Learn More on Laura Sepp-Lorenzino's age.
What is Laura Sepp-Lorenzino's salary?
As the EVP of Intellia Therapeutics, Inc., Dr. Sepp-Lorenzino earns $670,580.00 per year. There are 4 executives that earn more than Dr. Sepp-Lorenzino. The highest earning executive at Intellia Therapeutics is Mr. Nessan Bermingham Ph.D., Founder & Member of Scientific Advisor Board, who commands a salary of $1,380,000.00 per year. Learn More on Laura Sepp-Lorenzino's salary.
How do I contact Laura Sepp-Lorenzino?
Has Laura Sepp-Lorenzino been buying or selling shares of Intellia Therapeutics?
Laura Sepp-Lorenzino has not been actively trading shares of Intellia Therapeutics during the last quarter. Most recently, Laura Sepp-Lorenzino sold 2,275 shares of the business's stock in a transaction on Monday, January 8th. The shares were sold at an average price of $28.87, for a transaction totalling $65,679.25. Following the completion of the sale, the executive vice president now directly owns 43,927 shares of the company's stock, valued at $1,268,172.49. Learn More on Laura Sepp-Lorenzino's trading history.
Who are Intellia Therapeutics' active insiders?
Are insiders buying or selling shares of Intellia Therapeutics?
In the last year, insiders at the sold shares 7 times. They sold a total of 37,420 shares worth more than $1,085,489.31. The most recent insider tranaction occured on October, 2nd when CAO Michael P Dube sold 2,012 shares worth more than $38,248.12. Insiders at Intellia Therapeutics own 3.2% of the company.
Learn More about insider trades at Intellia Therapeutics. Information on this page was last updated on 10/2/2024.
